1.0SOMOhttps://www.somo.nl/nlPrivate gains we can ill afford - SOMOrich600338<blockquote class="wp-embedded-content" data-secret="98sPj55Sx0"><a href="https://www.somo.nl/nl/private-gains-we-can-ill-afford/">Private gains we can ill afford</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.somo.nl/nl/private-gains-we-can-ill-afford/embed/#?secret=98sPj55Sx0" width="600" height="338" title="“Private gains we can ill afford” — SOMO" data-secret="98sPj55Sx0" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
https://www.somo.nl/nl/wp-content/uploads/sites/2/2020/04/Rapport-The-financialisation-of-Big-Pharma-cover.jpg7441052Dit rapport onderzoekt de financialisering van de farmaceutische sector. In dit bedrijfsmodel draait om het maximaliseren van uitbetalingen aan de aandeelhouders, ten koste van productieve investeringen (in dit geval medicijnproductie en -ontwikkeling). Dit heeft vergaande maatschappelijke gevolgen, waaronder hoge medicijnprijzen....